查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466547

間質幹細胞市場：按類型、適應症、分離來源、應用分類 - 2024-2030 年全球預測

Mesenchymal Stem Cells Market by Type (Allogeneic, Autologous), Indication (Bone & Cartilage Repair, Cancer, Cardiovascular Disease), Source of Isolation, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

間質幹細胞市場規模預計2023年為35.1億美元，2024年達39.8億美元，預計2030年將達到85.9億美元，複合年成長率為13.63%。

間質幹細胞（MSC）是多功能基質細胞，可分化成各種細胞類型，如成骨細胞、軟骨細胞、肌肉細胞和脂肪細胞。這些細胞透過其黏附於塑膠表面的能力以及在特定條件下培養時特定表面標誌物的表達來識別。間質幹細胞從多種組織中採集，包括骨髓、脂肪組織、臍帶血和牙髓。推動間質幹細胞擴大用途的關鍵因素包括其可再生、免疫調節特性以及在治療骨關節炎、心血管疾病和移植物抗宿主疾病等各種疾病中的用途。此外，再生醫學和作為基因治療的遞送載體的新應用的潛力進一步增加了研究和工業界的興趣。然而，MSC的使用存在免疫排斥的風險和惡性的可能性。為了解決這些問題，間質幹細胞分離和培養技術的標準化以及開發穩健的體外擴增和品管通訊協定非常重要。組織工程的進步和3D生物列印技術的發展可能使利用間質幹細胞建構複雜的組織和器官成為可能。此外，對個人化醫療的日益重視可能會帶來更有針對性和更有效的基於間質幹細胞的治療。

主要市場統計
基準年[2023] 35.1億美元
預測年份 [2024] 39.8億美元
預測年份 [2030] 85.9億美元
複合年成長率（%） 13.63%

自體間質幹細胞具有免疫安全性和個人化性質，有利於長期治療。

同種異體間質幹細胞源自供體，經過擴增和儲存以供各種受體使用。這些細胞在擴充性和即時可用性方面具有優勢，這在急性護理環境中非常重要。當患者需要立即介入並且沒有時間或能力捐贈自己的細胞時，通常需要使用同種異體 MSC。此外，健康狀況不佳或某些遺傳性疾病的患者可能會從同種異體間質幹細胞中獲益更多，以避免使用潛在不健康細胞的風險。由於自體間質幹細胞是從患者自身體內收集的，因此它們出現免疫排斥的可能性較小，並且避免了與捐贈者採購相關的倫理考量。當計劃治療時，例如慢性或退化性疾病疾病，自體 MSC 是首選。這種個體化確保了相容性並降低了免疫反應的風險。

用於 CVD 治療適應症的 MSC 的大量研發活動

骨關節炎、類風濕性關節炎和骨質疏鬆症的盛行率不斷增加，以及改善骨折癒合的需要，推動了骨骼和軟骨修復對 MSC 的需求。間質幹細胞至關重要，因為它們有可能分化成成骨細胞和軟骨細胞，從而為修復受損的骨骼和軟骨組織提供再生選擇。間質幹細胞代表了一種新的癌症治療方法，特別是因為它們具有腫瘤部位的歸巢能力和抗癌藥物傳遞的潛力。心血管疾病 (CVD) 是全世界死亡的主要原因，間質幹細胞因其再生受損心臟組織的潛力而受到關注。由於心臟組織的再生能力有限，因此對這種應用的需求非常迫切。移植物抗宿主疾病（GvHD）是造血幹細胞移植的嚴重併發症。 MSC具有免疫調節特性，適合治療GvHD。間質幹細胞的免疫調節作用有潛力作為治療自體免疫疾病和發炎疾病（如多發性硬化症、紅斑性狼瘡和克隆氏症）的藥物。這些疾病是慢性的，現有的治療方法不足，因此迫切需要新的治療方法。肝硬化、肝炎等肝病都會導致肝功能衰竭，肝臟移植是唯一的治療方法。間質幹細胞療法可以透過促進肝臟再生和纖維化修復來提供一種侵入性較小的替代療法。

分離來源：骨髓間質幹細胞的高細胞產量和已建立的治療用途

脂肪組織來源的間質幹細胞（AD-MSCs）通常是在抽脂過程中從脂肪組織中收穫的。 AD-MSCs豐富且易於收穫，每克組織的MSCs產量高。 AD-MSC 表現出強大的分化潛力，是再生醫學和化妝品應用的理想選擇。骨髓間質幹細胞（BM-MSCs）因其高分化潛力而成為研究最廣泛的間質幹細胞之一。骨髓間質幹細胞常用於治療血液疾病以及修復骨骼和軟骨。臍帶血來源的間質幹細胞是從出生後的臍帶血中收集的。臍帶血來源的間質幹細胞比其他來源的間質幹細胞成熟度較低，可能會影響其免疫調節功能。從輸卵管分離出的間質幹細胞由於其胚胎樣特性而成為再生醫學中有前途的新來源。胎兒肝臟來源的 MSC 因其高增殖率和產生各種細胞類型的潛力而被鑑定。其用途主要集中在研究，特別是肝病和肝再生。肺源性間質幹細胞由於其部位特異性優勢，可用於呼吸系統疾病的研究與治療。從週邊血液中採集的間質幹細胞具有透過侵入性較小的過程採集的優點。週邊血液來源的 MSC 是骨髓和脂肪組織來源的 MSC 的非侵入性替代品，但周邊血液中 MSC 的濃度要低得多，這使得它們難以分離，並可能限制臨床應用。

間質幹細胞由於能夠模擬人類應用疾病並測試藥物療效，在疾病建模和藥物發現方面具有優勢

間質幹細胞擴大用於疾病建模，以了解各種疾病的病理學。研究人員優先利用間質幹細胞，因為它們能夠分化成多種細胞類型並具有免疫調節特性。間質幹細胞在藥物開發和藥物發現的早期階段發揮重要作用。它們的分化潛力使研究人員能夠觀察新藥對 MSC 衍生的各種細胞類型的影響。這對於發現新治療方法和了解藥物機制至關重要。幹細胞銀行正成為間質幹細胞的重要應用，私人和公共銀行為未來的治療應用提供儲存服務。組織工程是一個不斷發展的領域，間質幹細胞對於開發修復或替換受損組織的生物替代品至關重要。 MSC 也用於體外毒性測試，以評估化學物質和藥物的安全性。間質幹細胞的多功能使其特別適合預測多種細胞類型的毒性。

區域洞察

參與間質幹細胞（MSC）研究和治療開發的生物技術公司在美洲，特別是在美國和加拿大擁有強大的影響力，這得益於細胞治療產品的大量投資和有利的監管趨勢。在FDA對幹細胞治療和先進醫療基礎設施的前瞻性立場的推動下，這些國家擴大將間質幹細胞用於骨關節炎、創傷治療和移植物抗宿主疾病等臨床試驗。在以中國、日本和韓國為代表的亞太地區，人們對間質幹細胞的興趣不斷成長且迅速成長，各國政府積極推動再生醫學作為科學進步的重要領域。亞太地區的公司正在大力投資擴大生產能力並建立國際合作，以加強間質幹細胞的研究和臨床應用。歐洲、中東和非洲地區的情況好壞參半，歐洲國家也遵守與美洲類似的嚴格監管標準。歐洲藥品管理局 (EMA) 提供全面的法規結構，確保 MSC 產品的安全性和有效性。然而，歐洲有一些專門從事幹細胞研究的先驅公司和研究機構，非常注重品質和製造控制以及品管規範（GMP）的遵守。

FPNV定位矩陣

FPNV定位矩陣對於評估間質幹細胞市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對間質幹細胞市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估及資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.間質幹細胞市場規模及預測為何？

間質幹細胞市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.間質幹細胞市場的技術趨勢和法規結構是什麼？

4.間質幹細胞市場主要廠商的市場佔有率為何？

5.進入間間質幹細胞市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 間質幹細胞的生長研究
      • 老年人口增加和慢性病增加
      • 幹細胞治療的持續前景
    • 抑制因素
      • 幹細胞治療缺乏標準化和監管
    • 機會
      • 間質幹細胞的新應用
      • 擴大間質幹細胞產品合作和夥伴關係並推動治療創新
    • 任務
      • 與人類 MSC 治療相關的倫理和安全問題
  • 市場區隔分析
    • 類型：自體間質幹細胞的免疫安全性和個人化使其有利於長期治療
    • 適應症：用於 CVD 治療的 MSC 的大量研發活動
    • 分離來源：骨髓間質幹細胞的高細胞產量和已建立的治療用途
    • 應用：間質幹細胞由於能夠模擬人類疾病和測試藥物療效，在疾病建模和藥物發現方面具有優勢
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章間間質幹細胞市場：依類型

  • 同種異體的
  • 自體移植

第7章間間質幹細胞市場：依適應症分類

  • 骨頭和軟骨修復
  • 癌症
  • 循環系統疾病
  • 移植物抗宿主疾病
  • 發炎和免疫疾病
  • 肝病

第8章間質幹細胞市場：依隔離來源

  • 脂肪組織
  • 骨髓
  • 臍帶血
  • 輸卵管
  • 胎兒肝臟
  • 肺
  • 週邊血

第9章間間質幹細胞市場：依應用分類

  • 疾病模型
  • 藥物開發和發現
  • 幹細胞銀行
  • 人體組織工程
  • 毒理學研究

第10章 北美及南美間質幹細胞市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太間間質幹細胞市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲間間質幹細胞市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Cellcolabs 宣布與 REPROCELL 合作
    • PromoCell 推出 PromoExQ MSC 生長培養基 XF，用於符合 GMP 的間間質幹細胞分離與擴增
    • Pluristyx 和 Stemmatters 宣布合作開發和製造 iPSC 衍生的 MSC 銀行

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-B973EDD5ED66

[189 Pages Report] The Mesenchymal Stem Cells Market size was estimated at USD 3.51 billion in 2023 and expected to reach USD 3.98 billion in 2024, at a CAGR 13.63% to reach USD 8.59 billion by 2030.

Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. These cells are identified by their ability to adhere to plastic surfaces when cultured under specific conditions and by the expression of certain surface markers. MSCs are harvested from various tissues, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. The major factors driving the expansion of their use include their regenerative potential, immunomodulatory properties, and their use in treating various diseases, such as osteoarthritis, cardiovascular disease, and graft-versus-host disease. Additionally, their potential in emerging regenerative medicine applications and as delivery vehicles for gene therapy has further catalyzed research and industry interest. However, there is a risk of immune rejection and potential for malignant transformation with the use of MSCs. To address these issues, standardization of MSC isolation and culture techniques is critical, as well as the development of robust protocols for in vitro expansion and quality control. Advances in tissue engineering and the development of 3D bioprinting technologies may allow for the construction of complex tissues and organs using MSCs. Additionally, the growing emphasis on personalized medicine is likely to lead to more targeted and effective MSC-based therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 3.51 billion
Estimated Year [2024] USD 3.98 billion
Forecast Year [2030] USD 8.59 billion
CAGR (%) 13.63%

Type: Immunological safety and personalized nature of autologous MSCs to make them beneficial for long-term treatments

Allogeneic MSCs are derived from a donor, which are then expanded and stored for use in different recipients. These cells have an advantage in scalability and immediate availability, which is critical in acute care scenarios. Allogeneic MSCs are often indicated in cases where patients require immediate intervention and may not have the time or ability to donate their own cells. In addition, individuals with compromised health or certain genetic disorders may benefit more from allogeneic MSCs to avoid the risks of using their potentially unhealthy cells. Autologous MSCs are harvested from the patient's own body, which diminishes the likelihood of immune rejection and avoids the ethical considerations associated with donor sourcing. Autologous MSCs are preferred in chronic conditions or when treatments are planned, such as for degenerative diseases. This personalization ensures compatibility and a lower risk of immune response.

Indication: Substantial research and development activities on MSCs for the treatment of CVDs

The need for mesenchymal stem cells (MSCs) in bone and cartilage repair is driven by the increasing prevalence of osteoarthritis, rheumatoid arthritis, and osteoporosis, as well as the necessity for improved healing of bone fractures. MSCs are pivotal for their potential to differentiate into osteoblasts and chondrocytes, thereby providing a regenerative option for repairing damaged bone and cartilaginous tissues. MSCs represent a novel therapeutic approach for cancer treatment, particularly due to their homing capabilities to tumor sites and their potential to deliver anti-cancer agents. Cardiovascular diseases (CVD) are a leading cause of death globally, and MSCs have gained attention for their potential to regenerate damaged heart tissue. The need for this application is pressing due to the limited regenerative capacity of the cardiac tissue. Graft-versus-host disease (GvHD) is a severe complication of hematopoietic stem cell transplantation. MSCs have immunomodulatory properties that make them a suitable treatment for managing GvHD. MSCs' immunomodulatory effects serve as a potential therapy for autoimmune and inflammatory diseases such as multiple sclerosis, lupus, and Crohn's disease. These conditions have a high need for new therapies due to their chronic nature and the inadequacy of existing treatments. Liver diseases, such as cirrhosis and hepatitis, can lead to liver failure, for which liver transplantation is the only definitive treatment. MSC therapies could offer a less invasive alternative by promoting liver regeneration and fibrosis repair.

Source of Isolation: High cell yield and established therapeutic use of bone-marrow derived MSC

Adipose tissue-derived MSCs (AD-MSCs) are obtained from fat tissues, often during liposuction procedures. They are abundant and easy to harvest, with a high yield of MSCs per gram of tissue. AD-MSCs exhibit a strong capacity for differentiation, making them ideal for regenerative medicine and cosmetic applications. Bone marrow-derived MSCs (BM-MSCs) are one of the most extensively studied MSC types due to their high differentiation potential. They are often used in treating hematological diseases and repairing bone and cartilage. Cord blood-derived MSCs are collected from the umbilical cord blood after childbirth, a non-invasive and ethically uncontroversial source. They are less mature than MSCs from other sources, which may have implications for their immunomodulatory functions. Mesenchymal stem cells isolated from the fallopian tube are a novel source with a promising future in regenerative medicine due to their embryonic-like properties. Fetal liver-derived MSCs have been identified for their high proliferation rate and potential to generate a variety of cell types. Their use is primarily research-focused, with particular interest in liver diseases and hepatic regeneration. Lung-derived MSCs are valuable for studying and treating respiratory diseases due to their site-specific advantages. Mesenchymal stem cells obtained from peripheral blood have the advantage of being harvested through a less invasive process. They offer a non-invasive alternative to bone marrow and adipose tissue sources, but the MSCs found in peripheral blood are in far lower concentrations, which can complicate isolation and limit their clinical applications.

Application: Benefits of MSCs in disease modeling and drug discovery due to their ability to mimic human diseases and test drug efficacy

MSCs are increasingly being utilized in disease modeling to understand the pathophysiology of various disorders. Researchers prioritize MSCs for their ability to differentiate into multiple cell types and for their immunomodulatory properties. MSCs play a crucial role in the early phases of drug development and discovery. Their differentiation capabilities enable researchers to observe the effects of new drugs on various cell types derived from MSCs. This is essential for discovering new therapies and understanding drug mechanisms. Stem cell banking has emerged as an important application for MSCs, with private and public banks offering storage services for future therapeutic use. Tissue engineering is a growing field where MSCs are essential for the development of biological substitutes to repair or replace damaged tissues. MSCs are also used for in vitro toxicology studies to evaluate the safety of chemicals and drugs. MSCs' multipotency makes them particularly suited for predicting toxicity in multiple cell types.

Regional Insights

In the Americas, particularly the United States and Canada, there is a robust presence of biotechnology firms engaged in mesenchymal stem cell (MSCs) research and therapy development, supported by significant investment and favorable regulatory pathways for cell therapy products. These countries are major in clinical trials involving MSCs, focusing on applications such as osteoarthritis, wound healing, and graft-versus-host disease, propelled by the FDA's progressive stance on stem cell therapies and advanced healthcare infrastructure. The APAC region, led by countries such as China, Japan, and South Korea, showcases a dynamic and rapidly growing interest in MSCs, with governments actively promoting regenerative medicine as a key area for scientific advancement. APAC companies are investing heavily in scaling up manufacturing capabilities and in establishing international collaborations to enhance both research and clinical application of MSCs. The EMEA region presents a mixed scenario, with European countries adhering to stringent regulatory standards similar to those in the Americas. The European Medicines Agency (EMA) offers a comprehensive regulatory framework that ensures the safety and efficacy of MSC products. Nonetheless, Europe is home to several pioneering companies and research institutions dedicated to stem cell research, with a focus on quality and adherence to Good Manufacturing Practice (GMP) standards.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Mesenchymal Stem Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Mesenchymal Stem Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Mesenchymal Stem Cells Market, highlighting leading vendors and their innovative profiles. These include AMS Biotechnology, Astellas Pharma Inc., Athersys, Inc., Axol Biosciences Ltd., BrainStorm Cell Therapeutics Inc., Cell Applications, Inc., Celprogen, Inc., Cyagen Biosciences, Inc., Cytori Therapeutics Inc., Genlantis, Inc., Globus Medical, Hope Biosciences, LLC, Lonza Group AG, Merck KGaA, Mesoblast Limited, Neuromics, Pluri Biotech Ltd., PromoCell GmbH, R&D Systems, Inc., ScienCell Research Laboratories, Inc., Smith & Nephew PLC, Stemcell Technologies Inc., Stemedica Cell Technologies, Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Mesenchymal Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Allogeneic
    • Autologous
  • Indication
    • Bone & Cartilage Repair
    • Cancer
    • Cardiovascular Disease
    • GvHD
    • Inflammatory & Immunological Disease
    • Liver Diseases
  • Source of Isolation
    • Adipose Tissues
    • Bone Marrow
    • Cord Blood
    • Fallopian Tube
    • Fetal Liver
    • Lung
    • Peripheral Blood
  • Application
    • Disease Modeling
    • Drug Development & Discovery
    • Stem Cell Banking
    • Tissue Engineering
    • Toxicology Studies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Mesenchymal Stem Cells Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Mesenchymal Stem Cells Market?

3. What are the technology trends and regulatory frameworks in the Mesenchymal Stem Cells Market?

4. What is the market share of the leading vendors in the Mesenchymal Stem Cells Market?

5. Which modes and strategic moves are suitable for entering the Mesenchymal Stem Cells Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growth in Mesenchymal Stem Cell-Based Research
      • 5.1.1.2. Rising Geriatric Population Coupled with Growth in Chronic Diseases
      • 5.1.1.3. Continuously Evolving Landscape of Stem Cell Therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of Standardized and Regulated Delivery of Stem Cell Therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging Applications of Mesenchymal Stem Cells
      • 5.1.3.2. Growing Collaborations and Partnerships and Advancing Therapeutic Innovations of Mesenchymal Stem Cell Products
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical & Safety Issues Associated with Human MSC Therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Immunological safety and personalized nature of autologous MSCs to make them beneficial for long-term treatments
    • 5.2.2. Indication: Substantial research and development activities on MSCs for the treatment of CVDs
    • 5.2.3. Source of Isolation: High cell yield and established therapeutic use of bone-marrow derived MSC
    • 5.2.4. Application: Benefits of MSCs in disease modeling and drug discovery due to their ability to mimic human diseases and test drug efficacy
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Mesenchymal Stem Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Allogeneic
  • 6.3. Autologous

7. Mesenchymal Stem Cells Market, by Indication

  • 7.1. Introduction
  • 7.2. Bone & Cartilage Repair
  • 7.3. Cancer
  • 7.4. Cardiovascular Disease
  • 7.5. GvHD
  • 7.6. Inflammatory & Immunological Disease
  • 7.7. Liver Diseases

8. Mesenchymal Stem Cells Market, by Source of Isolation

  • 8.1. Introduction
  • 8.2. Adipose Tissues
  • 8.3. Bone Marrow
  • 8.4. Cord Blood
  • 8.5. Fallopian Tube
  • 8.6. Fetal Liver
  • 8.7. Lung
  • 8.8. Peripheral Blood

9. Mesenchymal Stem Cells Market, by Application

  • 9.1. Introduction
  • 9.2. Disease Modeling
  • 9.3. Drug Development & Discovery
  • 9.4. Stem Cell Banking
  • 9.5. Tissue Engineering
  • 9.6. Toxicology Studies

10. Americas Mesenchymal Stem Cells Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Mesenchymal Stem Cells Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Mesenchymal Stem Cells Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Cellcolabs Announces Partnership With REPROCELL for Research And GMP Grade MSC And MSC Derivatives
    • 13.3.2. PromoCell Launches PromoExQ MSC Growth Medium XF for GMP-Compliant Isolation and Expansion of Mesenchymal Stem Cells
    • 13.3.3. Pluristyx and Stemmatters Announce Partnership to Develop and Manufacture iPSC-derived MSC Banks

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. MESENCHYMAL STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. MESENCHYMAL STEM CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MESENCHYMAL STEM CELLS MARKET DYNAMICS
  • FIGURE 7. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. MESENCHYMAL STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. MESENCHYMAL STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MESENCHYMAL STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY BONE & CARTILAGE REPAIR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY BONE & CARTILAGE REPAIR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY GVHD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY GVHD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INFLAMMATORY & IMMUNOLOGICAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INFLAMMATORY & IMMUNOLOGICAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY LIVER DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY LIVER DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY ADIPOSE TISSUES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY ADIPOSE TISSUES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CORD BLOOD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CORD BLOOD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY FALLOPIAN TUBE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY FALLOPIAN TUBE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY FETAL LIVER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY FETAL LIVER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY LUNG, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY LUNG, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY DRUG DEVELOPMENT & DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY DRUG DEVELOPMENT & DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY STEM CELL BANKING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY STEM CELL BANKING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 138. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 139. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 146. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 147. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 154. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 155. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 162. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 163. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 170. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 178. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 179. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 194. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 195. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 202. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 203. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 208. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 209. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 210. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 211. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 223. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 228. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 229. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 236. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 237. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 244. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 245. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 252. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 253. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 260. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 261. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 268. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 269. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 276. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 277. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 284. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 290. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 291. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 292. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 293. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 300. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 301. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 306. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 307. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 308. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 309. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 310. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 311. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 314. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 315. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 316. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 317. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 318. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 319. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 323. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 324. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 325. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 330. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 331. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
  • TABLE 332. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
  • TABLE 333. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. SOUTH AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 338. SOUTH AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATIO